CA2029419C - Nmda-blocking pharmaceutical compositions - Google Patents
Nmda-blocking pharmaceutical compositions Download PDFInfo
- Publication number
- CA2029419C CA2029419C CA002029419A CA2029419A CA2029419C CA 2029419 C CA2029419 C CA 2029419C CA 002029419 A CA002029419 A CA 002029419A CA 2029419 A CA2029419 A CA 2029419A CA 2029419 C CA2029419 C CA 2029419C
- Authority
- CA
- Canada
- Prior art keywords
- composition according
- designates
- treatment
- compound
- chained
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract description 8
- 150000001875 compounds Chemical class 0.000 claims abstract description 61
- 239000000203 mixture Substances 0.000 claims abstract description 48
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims abstract description 23
- 206010010904 Convulsion Diseases 0.000 claims abstract description 20
- 229930195712 glutamate Natural products 0.000 claims abstract description 20
- 206010029350 Neurotoxicity Diseases 0.000 claims abstract description 13
- 206010044221 Toxic encephalopathy Diseases 0.000 claims abstract description 13
- 210000003169 central nervous system Anatomy 0.000 claims abstract description 13
- 230000007135 neurotoxicity Effects 0.000 claims abstract description 13
- 231100000228 neurotoxicity Toxicity 0.000 claims abstract description 13
- 239000004480 active ingredient Substances 0.000 claims abstract description 9
- 208000014674 injury Diseases 0.000 claims abstract description 9
- 206010021143 Hypoxia Diseases 0.000 claims abstract description 8
- 230000002035 prolonged effect Effects 0.000 claims abstract description 8
- 230000002829 reductive effect Effects 0.000 claims abstract description 8
- 125000002252 acyl group Chemical group 0.000 claims abstract description 7
- 125000004432 carbon atom Chemical group C* 0.000 claims abstract description 7
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract description 7
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract description 7
- 208000024827 Alzheimer disease Diseases 0.000 claims abstract description 6
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims abstract description 6
- 208000010496 Heart Arrest Diseases 0.000 claims abstract description 6
- 230000036770 blood supply Effects 0.000 claims abstract description 6
- 229910052799 carbon Inorganic materials 0.000 claims abstract description 6
- 230000001684 chronic effect Effects 0.000 claims abstract description 6
- 230000001010 compromised effect Effects 0.000 claims abstract description 6
- 239000008103 glucose Substances 0.000 claims abstract description 6
- 230000001146 hypoxic effect Effects 0.000 claims abstract description 6
- 230000000302 ischemic effect Effects 0.000 claims abstract description 6
- 208000015122 neurodegenerative disease Diseases 0.000 claims abstract description 6
- 230000008733 trauma Effects 0.000 claims abstract description 6
- 230000002461 excitatory amino acid Effects 0.000 claims abstract description 5
- 239000003257 excitatory amino acid Substances 0.000 claims abstract description 5
- 230000004770 neurodegeneration Effects 0.000 claims abstract description 5
- 150000003254 radicals Chemical class 0.000 claims abstract 4
- -1 1, 1 -dimethylheptyl Chemical group 0.000 claims description 18
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical group CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 14
- 239000000839 emulsion Substances 0.000 claims description 14
- 208000005374 Poisoning Diseases 0.000 claims description 12
- 231100000572 poisoning Toxicity 0.000 claims description 12
- 230000000607 poisoning effect Effects 0.000 claims description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 10
- KWVPFECTOKLOBL-KTKRTIGZSA-N 2-[(z)-octadec-9-enoxy]ethanol Chemical compound CCCCCCCC\C=C/CCCCCCCCOCCO KWVPFECTOKLOBL-KTKRTIGZSA-N 0.000 claims description 9
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical group CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 claims description 9
- QMGVPVSNSZLJIA-UHFFFAOYSA-N Nux Vomica Natural products C1C2C3C4N(C=5C6=CC=CC=5)C(=O)CC3OCC=C2CN2C1C46CC2 QMGVPVSNSZLJIA-UHFFFAOYSA-N 0.000 claims description 9
- 239000006184 cosolvent Substances 0.000 claims description 8
- LHNKBXRFNPMIBR-UHFFFAOYSA-N Picrotoxin Natural products CC(C)(O)C1(O)C2OC(=O)C1C3(O)C4OC4C5C(=O)OC2C35C LHNKBXRFNPMIBR-UHFFFAOYSA-N 0.000 claims description 7
- VJKUPQSHOVKBCO-AHMKVGDJSA-N picrotoxin Chemical compound O=C([C@@]12O[C@@H]1C[C@]1(O)[C@@]32C)O[C@@H]3[C@H]2[C@@H](C(=C)C)[C@@H]1C(=O)O2.O=C([C@@]12O[C@@H]1C[C@]1(O)[C@@]32C)O[C@@H]3[C@H]2[C@@H](C(C)(O)C)[C@@H]1C(=O)O2 VJKUPQSHOVKBCO-AHMKVGDJSA-N 0.000 claims description 7
- 239000003814 drug Substances 0.000 claims description 6
- 208000023105 Huntington disease Diseases 0.000 claims description 5
- 208000027089 Parkinsonian disease Diseases 0.000 claims description 5
- 206010034010 Parkinsonism Diseases 0.000 claims description 5
- 230000009692 acute damage Effects 0.000 claims description 5
- 239000003995 emulsifying agent Substances 0.000 claims description 5
- 239000003381 stabilizer Substances 0.000 claims description 5
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 claims description 4
- 238000006243 chemical reaction Methods 0.000 claims description 4
- 239000003085 diluting agent Substances 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- 238000000034 method Methods 0.000 claims description 4
- 239000012044 organic layer Substances 0.000 claims description 4
- 150000008065 acid anhydrides Chemical class 0.000 claims description 3
- 239000007957 coemulsifier Substances 0.000 claims description 3
- 239000002563 ionic surfactant Substances 0.000 claims description 3
- 230000001537 neural effect Effects 0.000 claims description 3
- 239000002736 nonionic surfactant Substances 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 3
- LOUSQMWLMDHRIK-IAGOWNOFSA-N (6ar,10ar)-9-(hydroxymethyl)-6,6-dimethyl-3-pentyl-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol Chemical compound C1C(CO)=CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 LOUSQMWLMDHRIK-IAGOWNOFSA-N 0.000 claims description 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims description 2
- 238000001914 filtration Methods 0.000 claims description 2
- 229910052943 magnesium sulfate Inorganic materials 0.000 claims description 2
- 235000019341 magnesium sulphate Nutrition 0.000 claims description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 2
- 239000012299 nitrogen atmosphere Substances 0.000 claims description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 claims description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims 2
- 229920001983 poloxamer Polymers 0.000 claims 2
- DCPSTSVLRXOYGS-UHFFFAOYSA-N 6-amino-1h-pyrimidine-2-thione Chemical compound NC1=CC=NC(S)=N1 DCPSTSVLRXOYGS-UHFFFAOYSA-N 0.000 claims 1
- 206010008748 Chorea Diseases 0.000 claims 1
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 claims 1
- 208000012601 choreatic disease Diseases 0.000 claims 1
- 238000001035 drying Methods 0.000 claims 1
- 238000001704 evaporation Methods 0.000 claims 1
- 230000002964 excitative effect Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000003960 organic solvent Substances 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 238000010898 silica gel chromatography Methods 0.000 claims 1
- 235000017557 sodium bicarbonate Nutrition 0.000 claims 1
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 abstract description 44
- 239000004471 Glycine Substances 0.000 abstract description 22
- 230000036461 convulsion Effects 0.000 abstract description 4
- 230000006378 damage Effects 0.000 abstract description 4
- 208000027418 Wounds and injury Diseases 0.000 abstract description 3
- 208000028867 ischemia Diseases 0.000 abstract description 3
- 206010008089 Cerebral artery occlusion Diseases 0.000 abstract description 2
- 230000017531 blood circulation Effects 0.000 abstract description 2
- CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical class C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 abstract description 2
- 229960004242 dronabinol Drugs 0.000 abstract description 2
- 230000007954 hypoxia Effects 0.000 abstract description 2
- 230000009467 reduction Effects 0.000 abstract description 2
- CBOIHMRHGLHBPB-UHFFFAOYSA-N hydroxymethyl Chemical compound O[CH2] CBOIHMRHGLHBPB-UHFFFAOYSA-N 0.000 abstract 2
- 102000015404 Amino Acid Receptors Human genes 0.000 abstract 1
- 108010025177 Amino Acid Receptors Proteins 0.000 abstract 1
- 208000034308 Grand mal convulsion Diseases 0.000 abstract 1
- 230000001154 acute effect Effects 0.000 abstract 1
- 239000002574 poison Substances 0.000 abstract 1
- 231100000614 poison Toxicity 0.000 abstract 1
- 230000027455 binding Effects 0.000 description 40
- 230000000694 effects Effects 0.000 description 24
- HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 description 23
- 241000699670 Mus sp. Species 0.000 description 19
- 108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 description 16
- 102000004868 N-Methyl-D-Aspartate Receptors Human genes 0.000 description 14
- 238000002474 experimental method Methods 0.000 description 14
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 12
- 238000010494 dissociation reaction Methods 0.000 description 10
- 206010044565 Tremor Diseases 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 8
- 241000452413 Sabra Species 0.000 description 8
- 230000005593 dissociations Effects 0.000 description 8
- 102000005962 receptors Human genes 0.000 description 8
- 108020003175 receptors Proteins 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- QMGVPVSNSZLJIA-FVWCLLPLSA-N strychnine Chemical compound O([C@H]1CC(N([C@H]2[C@H]1[C@H]1C3)C=4C5=CC=CC=4)=O)CC=C1CN1[C@@H]3[C@]25CC1 QMGVPVSNSZLJIA-FVWCLLPLSA-N 0.000 description 8
- 238000007920 subcutaneous administration Methods 0.000 description 8
- 230000036963 noncompetitive effect Effects 0.000 description 7
- 206010042008 Stereotypy Diseases 0.000 description 6
- 239000005557 antagonist Substances 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 239000003981 vehicle Substances 0.000 description 6
- 208000001871 Tachycardia Diseases 0.000 description 5
- 230000037396 body weight Effects 0.000 description 5
- 230000034994 death Effects 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 230000006794 tachycardia Effects 0.000 description 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- 241001279009 Strychnos toxifera Species 0.000 description 4
- 239000003963 antioxidant agent Substances 0.000 description 4
- 230000003078 antioxidant effect Effects 0.000 description 4
- 235000006708 antioxidants Nutrition 0.000 description 4
- 230000002920 convulsive effect Effects 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 230000001665 lethal effect Effects 0.000 description 4
- 230000001404 mediated effect Effects 0.000 description 4
- 239000012071 phase Substances 0.000 description 4
- JTJMJGYZQZDUJJ-UHFFFAOYSA-N phencyclidine Chemical compound C1CCCCN1C1(C=2C=CC=CC=2)CCCCC1 JTJMJGYZQZDUJJ-UHFFFAOYSA-N 0.000 description 4
- 230000003389 potentiating effect Effects 0.000 description 4
- 229960005453 strychnine Drugs 0.000 description 4
- 231100000419 toxicity Toxicity 0.000 description 4
- 230000001988 toxicity Effects 0.000 description 4
- 230000003512 tremorgenic effect Effects 0.000 description 4
- 150000003626 triacylglycerols Chemical class 0.000 description 4
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 102000018899 Glutamate Receptors Human genes 0.000 description 3
- 108010027915 Glutamate Receptors Proteins 0.000 description 3
- 229930195714 L-glutamate Natural products 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 108010057790 Tcp receptor Proteins 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 239000000556 agonist Substances 0.000 description 3
- 230000000202 analgesic effect Effects 0.000 description 3
- 230000003474 anti-emetic effect Effects 0.000 description 3
- 239000002111 antiemetic agent Substances 0.000 description 3
- 230000003542 behavioural effect Effects 0.000 description 3
- 230000003375 cannabimimetic effect Effects 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 230000001054 cortical effect Effects 0.000 description 3
- 208000018459 dissociative disease Diseases 0.000 description 3
- 230000032050 esterification Effects 0.000 description 3
- 238000005886 esterification reaction Methods 0.000 description 3
- 208000013403 hyperactivity Diseases 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 230000003137 locomotive effect Effects 0.000 description 3
- 230000006742 locomotor activity Effects 0.000 description 3
- 239000003703 n methyl dextro aspartic acid receptor blocking agent Substances 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 230000000506 psychotropic effect Effects 0.000 description 3
- 230000000707 stereoselective effect Effects 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- 102000004310 Ion Channels Human genes 0.000 description 2
- 108090000862 Ion Channels Proteins 0.000 description 2
- 229940127523 NMDA Receptor Antagonists Drugs 0.000 description 2
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 208000006011 Stroke Diseases 0.000 description 2
- 230000021736 acetylation Effects 0.000 description 2
- 238000006640 acetylation reaction Methods 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 230000001384 anti-glaucoma Effects 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 229930003827 cannabinoid Natural products 0.000 description 2
- 239000003557 cannabinoid Substances 0.000 description 2
- 230000002860 competitive effect Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 239000012154 double-distilled water Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 231100000225 lethality Toxicity 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000006959 non-competitive inhibition Effects 0.000 description 2
- 230000009871 nonspecific binding Effects 0.000 description 2
- 229950010883 phencyclidine Drugs 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 229960005235 piperonyl butoxide Drugs 0.000 description 2
- 229920001993 poloxamer 188 Polymers 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 238000000159 protein binding assay Methods 0.000 description 2
- 239000008247 solid mixture Substances 0.000 description 2
- 230000009870 specific binding Effects 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 2
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- LCQXXVFFJHBYME-UHFFFAOYSA-N 2-butyl-4-hydroxybenzoic acid Chemical class CCCCC1=CC(O)=CC=C1C(O)=O LCQXXVFFJHBYME-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 201000006474 Brain Ischemia Diseases 0.000 description 1
- FIPWRIJSWJWJAI-UHFFFAOYSA-N Butyl carbitol 6-propylpiperonyl ether Chemical compound C1=C(CCC)C(COCCOCCOCCCC)=CC2=C1OCO2 FIPWRIJSWJWJAI-UHFFFAOYSA-N 0.000 description 1
- IGZRNUALWQHOCA-UHFFFAOYSA-N CCCC(N)(C(O)=O)P(=O)=O Chemical compound CCCC(N)(C(O)=O)P(=O)=O IGZRNUALWQHOCA-UHFFFAOYSA-N 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 235000012766 Cannabis sativa ssp. sativa var. sativa Nutrition 0.000 description 1
- 235000012765 Cannabis sativa ssp. sativa var. spontanea Nutrition 0.000 description 1
- 206010008120 Cerebral ischaemia Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- 206010013457 Dissociation Diseases 0.000 description 1
- 206010013710 Drug interaction Diseases 0.000 description 1
- 102000011714 Glycine Receptors Human genes 0.000 description 1
- 108010076533 Glycine Receptors Proteins 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 239000004866 Hashish Substances 0.000 description 1
- 208000013016 Hypoglycemia Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229910010082 LiAlH Inorganic materials 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- 108010063843 Phencyclidine Receptors Proteins 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920002873 Polyethylenimine Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- CFXQEHVMCRXUSD-UHFFFAOYSA-N TCP Natural products ClCC(Cl)CCl CFXQEHVMCRXUSD-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000006931 brain damage Effects 0.000 description 1
- 231100000874 brain damage Toxicity 0.000 description 1
- 208000029028 brain injury Diseases 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 229940099352 cholate Drugs 0.000 description 1
- 239000003179 convulsant agent Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000008157 edible vegetable oil Substances 0.000 description 1
- 239000008344 egg yolk phospholipid Substances 0.000 description 1
- 229940068998 egg yolk phospholipid Drugs 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 235000020375 flavoured syrup Nutrition 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- LBOJYSIDWZQNJS-UHFFFAOYSA-N neurogard Chemical compound C12=CC=CC=C2C2(C)C3=CC=CC=C3CC1N2 LBOJYSIDWZQNJS-UHFFFAOYSA-N 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 230000007171 neuropathology Effects 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000012053 oil suspension Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- HLKWWJWIDARXEW-UHFFFAOYSA-N potassium;2-methylbutan-1-olate Chemical compound [K+].CCC(C)C[O-] HLKWWJWIDARXEW-UHFFFAOYSA-N 0.000 description 1
- 229940001470 psychoactive drug Drugs 0.000 description 1
- 239000004089 psychotropic agent Substances 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000006722 reduction reaction Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 238000011916 stereoselective reduction Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/78—Ring systems having three or more relevant rings
- C07D311/80—Dibenzopyrans; Hydrogenated dibenzopyrans
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Psychiatry (AREA)
- Toxicology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pyrane Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IL92238 | 1989-11-07 | ||
| IL9223889A IL92238A (en) | 1989-11-07 | 1989-11-07 | ADMN blocking product containing tetrahydrocannabinol history, several new tetrahydrocannabinol histories and process for their preparation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2029419A1 CA2029419A1 (en) | 1991-05-08 |
| CA2029419C true CA2029419C (en) | 2004-05-25 |
Family
ID=11060554
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002029419A Expired - Fee Related CA2029419C (en) | 1989-11-07 | 1990-11-07 | Nmda-blocking pharmaceutical compositions |
Country Status (11)
| Country | Link |
|---|---|
| EP (1) | EP0427518B1 (enExample) |
| JP (1) | JPH0768235B2 (enExample) |
| KR (1) | KR950005914B1 (enExample) |
| AT (1) | ATE119898T1 (enExample) |
| AU (1) | AU631262B2 (enExample) |
| CA (1) | CA2029419C (enExample) |
| DE (1) | DE69017839T2 (enExample) |
| DK (1) | DK0427518T3 (enExample) |
| ES (1) | ES2071786T3 (enExample) |
| IL (1) | IL92238A (enExample) |
| ZA (1) | ZA908914B (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6017903A (en) | 1996-09-27 | 2000-01-25 | Guilford Pharmaceuticals Inc. | Pharmaceutical compositions and methods of treating a glutamate abnormality and effecting a neuronal activity in an animal using NAALADase inhibitors |
| US5824662A (en) | 1996-09-27 | 1998-10-20 | Guilford Pharmaceuticals Inc. | Treatment of global and focal ischemia using naaladase inhibitors |
| EP1005348A1 (en) | 1996-09-27 | 2000-06-07 | Guilford Pharmaceuticals Inc. | Naaladase compositions and methods for treating glutamate abnormality and effecting neuronal activity in animals |
| DE19706903A1 (de) * | 1997-02-21 | 1998-08-27 | Bayer Ag | Verwendung von bekannten Agonisten des zentralen Cannabinoid-Rezeptors CB 1 |
| WO1998050027A1 (en) * | 1997-05-07 | 1998-11-12 | Unimed Pharmaceutical, Inc. | Method of improving disturbed behavior and elevating mood in humans |
| WO1999053917A1 (en) | 1998-04-21 | 1999-10-28 | The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Cannabinoids as antioxidants and neuroprotectants |
| CN102766128A (zh) | 2005-09-29 | 2012-11-07 | 阿尔巴尼分子研究公司 | δ-9-四氢大麻酚的生成方法 |
| DE102015112092B4 (de) | 2015-07-24 | 2022-03-10 | Beko Technologies Gmbh | Öl/Wasser-Trennvorrichtung mit Druckluftbeaufschlagung |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL48824A (en) * | 1976-01-12 | 1980-05-30 | Yissum Res Dev Co | Pharmaceutical compositions containing (3s,js) tetrahydrocanabinol derivatives and some novel compounds of this type |
| US4133819A (en) * | 1977-06-17 | 1979-01-09 | Pfizer Inc. | Hexahydro-1-hydroxy-9-hydroxymethyl-3-substituted-6H-dibenzo[b,d]pyrans as analgesic agents |
| US4209520A (en) * | 1977-06-17 | 1980-06-24 | Pfizer Inc. | Hexahydro-1-hydroxy-9-hydroxymethyl-3-substituted-6H-dibenzo[b,d]pyrans as analgesic agents |
| IL80411A (en) * | 1986-10-24 | 1991-08-16 | Raphael Mechoulam | Preparation of dibenzopyranol derivatives and pharmaceutical compositions containing them |
-
1989
- 1989-11-07 IL IL9223889A patent/IL92238A/en not_active IP Right Cessation
-
1990
- 1990-11-06 DK DK90312147.3T patent/DK0427518T3/da active
- 1990-11-06 ES ES90312147T patent/ES2071786T3/es not_active Expired - Lifetime
- 1990-11-06 EP EP90312147A patent/EP0427518B1/en not_active Expired - Lifetime
- 1990-11-06 AU AU65834/90A patent/AU631262B2/en not_active Ceased
- 1990-11-06 AT AT90312147T patent/ATE119898T1/de not_active IP Right Cessation
- 1990-11-06 DE DE69017839T patent/DE69017839T2/de not_active Expired - Fee Related
- 1990-11-07 KR KR1019900018114A patent/KR950005914B1/ko not_active Expired - Fee Related
- 1990-11-07 JP JP2302296A patent/JPH0768235B2/ja not_active Expired - Fee Related
- 1990-11-07 ZA ZA908914A patent/ZA908914B/xx unknown
- 1990-11-07 CA CA002029419A patent/CA2029419C/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| JPH0768235B2 (ja) | 1995-07-26 |
| DK0427518T3 (da) | 1995-07-24 |
| IL92238A (en) | 1995-07-31 |
| AU6583490A (en) | 1991-05-30 |
| AU631262B2 (en) | 1992-11-19 |
| KR950005914B1 (ko) | 1995-06-07 |
| EP0427518B1 (en) | 1995-03-15 |
| CA2029419A1 (en) | 1991-05-08 |
| DE69017839D1 (de) | 1995-04-20 |
| ES2071786T3 (es) | 1995-07-01 |
| JPH03209377A (ja) | 1991-09-12 |
| ZA908914B (en) | 1991-09-25 |
| ATE119898T1 (de) | 1995-04-15 |
| DE69017839T2 (de) | 1995-08-31 |
| EP0427518A1 (en) | 1991-05-15 |
| KR910009687A (ko) | 1991-06-28 |
| IL92238A0 (enExample) | 1990-07-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5284867A (en) | NMDA-blocking pharmaceutical compositions | |
| EP1299374B1 (en) | Novel non-psychotropic cannabinoids | |
| US6331560B1 (en) | Tumor necrosis factor alpha (TNF-α) inhibiting pharmaceuticals | |
| US6455580B1 (en) | Method and composition for antiviral therapy | |
| US20100292345A1 (en) | Therapeutic uses of cannabigerol | |
| WO2022129908A1 (en) | Cannabinoid derivative as a pharmaceutically active compound and method of preparation thereof | |
| US8513299B2 (en) | Methods of using low-dose doxepin for the improvement of sleep | |
| US20090042972A1 (en) | Methods of using low-dose doxepin for the improvement of sleep | |
| US20070213369A1 (en) | Novel non-psychotropic cannabinoids | |
| CA2029419C (en) | Nmda-blocking pharmaceutical compositions | |
| US20070060636A1 (en) | High enantiomeric purity dexanabinol for pharmaceutical compositions | |
| JPS58500995A (ja) | 緑内障治療用組成物 | |
| US20090068143A1 (en) | Orally effective cannabinoid analogs | |
| JPH0717859A (ja) | アラキドン酸代謝異常疾患治療剤 | |
| EP3927331A1 (en) | Pharmaceutical composition comprising tetrahydrocannabivarin for the prevention and treatment of overweight | |
| JP2025514339A (ja) | 疾患の処置に使用するための組成物 | |
| EP1785417A2 (en) | Novel non-psychotropic cannabinoids | |
| JPH07179340A (ja) | モノアミンオキシダーゼ阻害剤 | |
| WO1991012004A1 (en) | Topical use of 6-n-butyl-1,4,7,10-tetrahydro-4,10-dioxo-1,7-phenanthroline-2,8-dicarboxylic acid derivatives | |
| JPH11100377A (ja) | Ｈｉｖプロテアーゼ阻害物質 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKLA | Lapsed |